Regulatory

FDA’s Draft Guideline for Instructions for Use – Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic- Device Combination Products – Content and Format

FDA released Draft guidance provides recommendations for developing the content and format of an Instructions for Use (IFU) document for human prescription drug and biological products and drug-device or biologic-device combination products submitted under a new drug application (NDA) or a biologics license application (BLA). The IFU is developed by applicants for patients who use […]

Regulatory

FDA’s Draft Guideline for Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products

The US Food and Drug Administration (FDA) released one draft guidance on the content and format of the “Drug Abuse and Dependence” section of labeling. This guidance is intended to assist applicants in writing the DRUG ABUSE AND DEPENDENCE section of labeling, as described in the regulations for the content and format of labeling for […]

General Information

FDA’s Nextgen Portal to Submit Pre-Assigned ANDA Number Requests through the CDER

Prospective abbreviated new drug application (ANDA) applicants will be able to submit Pre-Assigned ANDA number requests via the CDER NextGen Portal. For Applicants with account holder account will be automatically updated with this Pre-Assigned ANDA number request functionality.  To create a new account, go to the CDER NextGen Portal, under the “Sign In” section on the right […]

General Information

Two more countries Bulgaria and Cyprus to benefit from EU-US mutual recognition agreement for inspections

The US Food and Drug Administration (FDA) confirmed the capability of two additional European Union (EU) Member States to carry out good manufacturing practice (GMP) inspections at a level equivalent to the United States (US). Bulgaria and Cyprus were included into the mutual recognition agreement between the EU and the US on 29 April 2019.

General Information

TGA Announced Labelling changes: information for health professionals

Quality Use of Medicines relies on clear medicine labels. To reduce medication errors, medicine labels need to be more consistent, with important information made more prominent and easier to read. Therapeutic Goods Administration has introduced improvements to help bring Australian medicine labels up to date and align them with international best practice and are designed […]

General Information

FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines

The Food and Drug Administration (FDA) is advising that rare but serious injuries have happened with certain common prescription insomnia medicines because of sleep behaviors, including sleepwalking, sleep driving, and engaging in other activities while not fully awake. These complex sleep behaviors have also resulted in deaths. These behaviors appear to be more common with […]

Book a Demo